HOME >> BIOLOGY >> NEWS
The PSA bounce Does it have clinical significance?

Using the largest known prostate cancer data set of patients treated solely with external-beam radiation in the U.S., radiation oncologists have examined the "PSA bounce" phenomenon and determined that it is not an indicator that men will die of prostate cancer any sooner than those men who do not experience a bounce. That is the result of a multi-institutional analysis presented today at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Atlanta, Ga.

The PSA (prostate-specific antigen) test is a blood test used for routine prostate cancer screening. The "PSA bounce" is a rise and then decline in the PSA level following radiation treatment for prostate cancer. The bounce phenomenon occurs in a third to half of men treated with radiation for prostate cancer. Urologists, radiation and medical oncologists have struggled with what a bouncing PSA means for a patient's prognosis, and how or if to offer further treatment.

"Because a steady rise in PSA can mean that cancer has recurred, physicians often interpret a bounce as the possibility that the cancer may still exist after treatment," explained Eric M. Horwitz, M.D., clinical director of the radiation oncology department at Fox Chase Cancer Center and lead author of the study. "Some physicians prescribe hormonal therapy in this situation, but hormones can have significant side effects for the patient, and may not be clinically necessary. For these reasons, it's important to develop clear guidelines."

In this retrospective analysis, data were gathered from the records of 4,839 men treated only with external-beam radiation between 1986 and 1995 at nine institutions throughout the US. The median follow-up was 6.3 years. Treatment during this time period consisted primarily of conventional radiation therapy, a lower dose than is generally used at academic cancer centers today, although some patients were treated with 3D conformal radiation therapy. In thi
'"/>

Contact: Colleen Kirsch
colleen.kirsch@fccc.edu
215-306-1211
Fox Chase Cancer Center
6-Oct-2004


Page: 1 2

Related biology news :

1. HIV-1 kills immune cells in the gut that may never bounce back
2. Phytoplankton bounce back from abrupt climate change
3. Fat kids can bounce back to normal blood pressure
4. Preclinical study links gene to brain aneurysm formation
5. Gene variant is associated with brain anatomy, clinical course of ADHD
6. New joint replacement material developed at MGH put to first clinical use
7. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
8. From clinical cancer research: rethinking therapeutic cancer vaccine trials
9. Manganese levels increase in scrapie-infected sheep before clinical symptoms develop
10. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
11. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2020)... (PRWEB) , ... April 23, 2020 , ... A team ... GenScript, is developing a synthetic antibody to SARS-CoV-2, the virus that causes coronavirus disease ... and would be another potential treatment option for COVID-19. , The efforts are being ...
(Date:4/22/2020)... ... April 21, 2020 , ... Captis ... venture capital firm that provides patent development support for early stage startups. The ... illnesses such as ovarian cancer and precancerous pancreatic lesions with simple, accurate and ...
(Date:4/18/2020)... Mass. (PRWEB) , ... April 16, 2020 , ... ... gene and cell therapy, today announced it will present a company update on its ... Virtual Investor Summit taking place on April 22 and 23. Dieter Lingelbach, the ...
Breaking Biology News(10 mins):
(Date:5/28/2020)... ... 28, 2020 , ... Genedata, the leading provider of enterprise ... ® 17.0, the latest version of its enterprise software for the automated analysis, ... will host a webinar on June 10, 2020, detailing and demonstrating the features ...
(Date:5/21/2020)... ... May 19, 2020 , ... Eaton Square is pleased to announce its growth ... a biotechnology and medical technology-focused strategy and M&A advisory firm. , This is an ... linking US and Asia Pacific healthcare innovators with capital and investors. , Popper and ...
(Date:5/15/2020)... ... May 15, 2020 , ... Sentien Biotechnologies, Inc., a ... Richard Ganz as Executive Chairman. Mr. Ganz will continue to lead Sentien’s Board ... as work closely with CEO Brian Miller and Sentien’s management team. , ...
(Date:5/9/2020)... ... , ... Worldwide Business with kathy ireland® will be LIVE ... 2020 and Wednesday, May 13, 2020 at 8:00pm ET / PT – prime ... from Techolution and Bravado Pharmaceuticals . , As leaders in ...
Breaking Biology Technology:
Cached News: